drugset

drugset / Trial / NCT00299806

SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension

NCT00299806 ↗

Phase 3 Completed 39 enrolled Novartis

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Assessing the safety and efficacy of SPP100 (Aliskiren) regimen in patients with severe hypertension

Timeline

Start: 2006-04
Primary completion: 2006-11
Completion: 2006-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aliskiren	Small molecule	—	—

Indications